Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Seminars in Oncology

• Publication date

  2010-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.seminoncol.2010.09.008PMID 21074066
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

  2010cited by this paper
• Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy

  2010cited by this paper
• CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells.

  2010cited by this paper
• Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in Mice

  2010cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Blockade of Programmed Death Ligand 1 Enhances the Therapeutic Efficacy of Combination Immunotherapy against Melanoma

  2010cited by this paper
• Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors

  2009cited by this paper
• In vivo depletion of DC impairs the anti‐tumor effect of agonistic anti‐CD137 mAb

  2009cited by this paper
• Palettes of Vaccines and Immunostimulatory Monoclonal Antibodies for Combination

  2009cited by this paper
• Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?

  2009cited by this paper
• Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.

  2008cited by this paper
• Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies.

  2008cited by this paper
• Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)

  2008cited by this paper
• Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity.

  2008cited by this paper
• Cytokine-Mediated Disruption of Lymphocyte Trafficking, Hemopoiesis, and Induction of Lymphopenia, Anemia, and Thrombocytopenia in Anti-CD137-Treated Mice1

  2007cited by this paper
• Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

  2007cited by this paper
• Immunostimulatory monoclonal antibodies for cancer therapy

  2007cited by this paper
• Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent.

  2007cited by this paper
• Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

  2007cited by this paper
• Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

  2006cited by this paper
• Significance of B7-H1 overexpression in kidney cancer.

  2006cited by this paper
• Eradication of established tumors in mice by a combination antibody-based therapy

  2006cited by this paper
• [Therapeutic effects of simultaneous expression of 4-1BBL and sPD-1 on experimental murine hepatoma].

  2006cited by this paper
• The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

  2006cited by this paper
• Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.

  2006cited by this paper
• Assessment of tissue biomarkers following anti-CD137 treatment in the EMT-6 mouse tumor model.

  2006cited by this paper
• TNF/TNFR family members in costimulation of T cell responses.

  2005cited by this paper
• Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.

  2005cited by this paper
• Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines

  2004cited by this paper
• Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo.

  2004cited by this paper
• Costimulation of human CD28– T cells by 4‐1BB ligand

  2003cited by this paper
• CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice.

  2003cited by this paper
• Involvement of tumor necrosis factor receptor superfamily (TNFRSF) members in the pathogenesis of inflammatory diseases

  2003cited by this paper
• Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.

  2002cited by this paper
• Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.

  2002cited by this paper
• Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease

  2002cited by this paper
• CTLA-4: new insights into its biological function and use in tumor immunotherapy

  2002cited by this paper
• 4-1BB Promotes the Survival of CD8+ T Lymphocytes by Increasing Expression of Bcl-xL and Bfl-11

  2002cited by this paper
• CD137 Expression in Tumor Vessel Walls

  2001cited by this paper
• CD137 expression in tumor vessel walls. High correlation with malignant tumors.

  2001cited by this paper
• Anti–4-1bb Monoclonal Antibodies Abrogate T Cell–Dependent Humoral Immune Responses in Vivo through the Induction of Helper T Cell Anergy

  1999cited by this paper
• Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal.

  1999cited by this paper

• Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors

  2025cites this paper
• Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families

  2025cites this paper
• A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies

  2024cites this paper
• CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production

  2024cites this paper
• Bispecific therapeutics: a state-of-the-art review on the combination of immune checkpoint ‎inhibition with costimulatory and non-checkpoint targeted therapy

  2024cites this paper
• Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications

  2023cites this paper
• CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

  2023cites this paper
• The apoptotic effects of NK-92 cells stimulated with an anti-CD226 antibody on MDA-MB-231 triple-negative breast cancer cells

  2023cites this paper
• Application of platform process development approaches to the manufacturing of Mabcalin™ bispecifics.

  2023cites this paper
• DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity

  2022cites this paper
• Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma

  2022cites this paper
• Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

  2022cites this paper
• Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy

  2022cites this paper
• An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation

  2022cites this paper
• Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer

  2022cites this paper
• Plasmid DNA cationic non-viral vector complexes induce cytotoxicity-associated PD-L1 expression up-regulation in cancer cells in vitro.

  2022cites this paper
• CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary.

  2022cites this paper
• Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma

  2022cites this paper
• CD137 Costimulation Enhances the Antitumor Activity of Vγ9Vδ2-T Cells in IL-10-Mediated Immunosuppressive Tumor Microenvironment

  2022cites this paper
• The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner

  2022cites this paper
• An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity

  2021cites this paper
• Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR

  2021cites this paper
• PD-1 and beyond to Activate T Cells in Cutaneous Squamous Cell Cancers: The Case for 4-1BB and VISTA Antibodies in Combination Therapy

  2021cites this paper
• Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics

  2021cites this paper
• miR-124-3p enhances dendritic cell-mediated anti-tumor immunity by targeting CYLD/4-1BBL pathway

  2021cites this paper
• Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors

  2021cites this paper
• Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4), and CD137 in cervical carcinoma.

  2021cites this paper
• PD‐1/PD‐L1‐dependent immune response in colorectal cancer

  2020cites this paper
• An In Vitro System Combining Tumor Cells and Lymphocytes to Predict the In Vivo Response of Immunomodulatory Antibodies

  2020cites this paper
• OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors

  2020cites this paper
• Combination of CpG Oligodeoxynucleotide and Anti-4-1BB Antibody in the Treatment of Multiple Hepatocellular Carcinoma in Mice

  2020cites this paper
• Overcoming Cancer Tolerance with Immune Checkpoint Blockade

  2020cites this paper
• CD137 costimulation enhances the antiviral activity of Vγ9Vδ2-T cells against influenza virus

  2020cites this paper
• Human cancer germline antigen-specific cytotoxic T cell—what can we learn from patient

  2020cites this paper
• Manipulation of the immune system for cancer defeat: a focus on the T cell inhibitory checkpoint molecules.

  2020cites this paper
• Lymph-directed immunotherapy - Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer.

  2020cites this paper
• 4‐1BB costimulation promotes bystander activation of human CD8 T cells

  2020cites this paper
• Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma

  2020influential citation
• An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses

  2020cites this paper
• Combination of CpG Oligodeoxynucleotide and Anti-4-1BB Antibody in the Treatment of Multiple Hepatocellular Carcinoma in Mice

  2020cites this paper
• Targeting monoamine oxidase A-regulated TAM polarization for cancer immunotherapy

  2020cites this paper
• Combination of CpG Oligodeoxynucleotide and Anti-4-1BB Antibody in the Treatment of Multiple Hepatocellular Carcinoma in Mice

  2020cites this paper
• Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343

  2019cites this paper
• From the Hellstrom paradox toward cancer cure.

  2019cites this paper
• Engineering Biomaterial Properties for T Cell Immunotherapy

  2019cites this paper
• CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy

  2019cites this paper
• Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

  2019cites this paper
• Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.

  2019cites this paper
• Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial

  2019cites this paper
• Immunity, Hypoxia and Metabolism - the ménage à trois of cancer: implications for immunotherapy.

  2019cites this paper
• Glucocorticoid resistance of allogeneic T cells alters the gene expression profile in the inflamed small intestine of mice suffering from acute graft-versus-host disease.

  2019cites this paper
• Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

  2019cites this paper
• Costimulation Induces CD4 T Cell Antitumor Immunity via an Innate-like Mechanism.

  2019influential citation
• Tumor Regression and Cure Depends on Sustained Th1 Responses

  2018cites this paper
• Emerging strategies for combination checkpoint modulators in cancer immunotherapy

  2018cites this paper
• Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy

  2018cites this paper
• The Role of Tumour Necrosis Factor Receptor Family Members CD137 (4-1BB) and CD30 in Antiviral T Cell Responses

  2018cites this paper
• IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy.

  2018cites this paper
• Adjuvant Therapy in the Treatment of Melanoma

  2018cites this paper
• Indications for the surgical resection of stage IV disease

  2018cites this paper
• TUMOR IMMUNOTHERAPY: MECHANISMS OF ACQUIRED RESISTANCE AND CHARACTERIZATION OF IMMUNE RELATED TOXICITIES

  2018cites this paper
• Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy

  2018cites this paper
• A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.

  2018cites this paper
• Immunomodulation with Adjuvants and Cytokines

  2018cites this paper
• Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non–Small‐Cell Lung Cancer: Where Do We Stand?

  2018cites this paper
• Engineering Platforms for T Cell Modulation.

  2018cites this paper
• Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation

  2018cites this paper
• Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer

  2018cites this paper
• The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies.

  2018cites this paper
• Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies

  2018cites this paper
• Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody

  2018cites this paper
• A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice

  2018cites this paper
• University of Groningen IgG 4 subclass-specific responses to Staphylococcus aureus antigens shed new light on host-pathogen interaction

  2017cites this paper
• Review: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer

  2017cites this paper
• New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone

  2017cites this paper
• Delivering safer immunotherapies for cancer

  2017cites this paper
• A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy.

  2017cites this paper
• Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy

  2017cites this paper
• Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities

  2017cites this paper
• Curing tumor-bearing mice by shifting a Th2 to a Th1 anti-tumor response

  2017cites this paper
• Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

  2017cites this paper
• The safety of anti PD-1 therapeutics for the treatment of melanoma

  2017cites this paper
• Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.

  2017cites this paper
• Combination immunotherapy: a road map

  2017cites this paper
• Predictors of responses to immune checkpoint blockade in advanced melanoma

  2017cites this paper
• Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia

  2017cites this paper
• Combination immunotherapy: a road map The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

  2017cites this paper
• Targeted tumor cell elimination by redirecting vaccination-induced CD8+ T cells in vivo with novel bifunctional peptide-MHC class I-IgG antibody fusions

  2017cites this paper
• CD137‐CRDI is not necessary in the role of contacting its natural ligand

  2017cites this paper
• T cell modulation in immunotherapy for hematological malignancies

  2017cites this paper
• Modeling Hepatocellular Toxicity of Enavatuzumab, a Humanized Anti-TweakR Antibody

  2017cites this paper
• Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma

  2017cites this paper
• TNFR A g onists : A Review of Current Biolo g ics Tar g etin g OX 40 , 4-1 BB , CD 27 , and GITR

  2017cites this paper
• Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF

  2017cites this paper
• S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity

  2017cites this paper
• Cell-mediated immunotherapy: its role in cancer treatment

  2017cites this paper
• TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

  2017cites this paper
• Memory Potential, Molecular Characterization, and Translational Applications of the Novel ThEO/TcEO T Cell Phenotype

  2017influential citation
• Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma

  2017cites this paper
• Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer.

  2016cites this paper